TCF12 Activates TGFB2 Expression to Promote the Malignant Progression of Melanoma
As one of the most common malignant tumors, melanoma is a serious threat to human health. More than half of melanoma patients have a BRAF mutation, and 90% of them have a BRAF(V600E) mutation. There is a targeted therapy for patients using a BRAF(V600E) inhibitor. However, no response to treatment i...
Main Authors: | Youjia Tian, Jiang Zhou, Xinxin Chai, Zejun Ping, Yurong Zhao, Xin Xu, Chi Luo, Jinghao Sheng |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/18/4505 |
Similar Items
-
Result Analysis of BRAF V600E Gene Mutation Using Molecular and Immunohistochemistry Detection in Acral Malignant Melanoma
by: Hermin Aminah Usman, et al.
Published: (2018-09-01) -
BRAF V600E Mutation in Malignant Melanoma—A Romanian Research Experience
by: Elena-Roxana Avădănei, et al.
Published: (2024-02-01) -
BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers
by: Giorgia Castellani, et al.
Published: (2023-08-01) -
Targeted Therapies for Melanoma
by: Karel Smetana, et al.
Published: (2020-09-01) -
Implicaciones diagnósticas, terapéuticas y pronósticas de la mutación BRAF V600E en melanomas cutáneos
by: Alberto José Piamo Morales
Published: (2019-05-01)